NEW YORK (TheStreet) -- Shares of Becton Dickinson  (BDX - Get Report)  were lower in mid-afternoon trading on Wednesday, ahead of the company's 2016 third-quarter results, due out before Thursday's opening bell. 

Becton Dickinson is expected to report earnings of $2.21 per share on revenues of $3.21 billion. Last year, the company posted earnings of $2.05 per share on revenues of $3.13 billion for the same quarter. 

The Franklin Lakes, NJ-based medical technology company's results should be helped by its rapidly expanding product portfolio, Zacks.com reports. Management at the company said it expects third-quarter growth to come from strong demand for its Pyxis ES platform and infusion pumps. 

The main headwind for Becton Dickinson is the unfavorable foreign exchange rate, Zacks.com said.  

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings team rates Becton Dickinson & Co. as a Buy with a ratings score of A-. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that the team rates. 

You can view the full analysis from the report here: BDX

BDX Chart BDX data by YCharts